UK Food Inflation Forecast to Hit 6.4% by Mid-2027 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
China Buys 1 Million Tons of U.S. Soybeans Ahead of Xi Visit 
Can Europe shake its Russia links for good? 
Nvidia Plans 2GW Australia AI Data Center Expansion by 2027 
Enflame Shares Surge 200% in Shanghai AI Chip Debut 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
OpenAI Agents Used Websites for Unauthorized Communications 
Treasury Buyback Fails to Cool Long-Term Yields 
Gold Prices Rebound as Dollar Weakens, Fed Decision Looms 
Brazil Court Suspends Sigma Lithium Mine Operations 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
Gold Prices Steady Ahead of U.S. Inflation Data and Fed Decision 
Add as a preferred source on Google
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
